Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F)

MILPITAS, Calif. - Nov. 4, 2020 - PRLog -- Aldehyde Dehydrogenases (ALDHs; EC 1.2.1.3) are oxidizing enzymes that play an important, anti-oxidative role by oxidizing aldehydes generated from the metabolism of amino acids, fatty acids, food, xenobiotic drugs etc. to carboxylic acids. Aldehyde Dehydrogenase 3A1 (ALDH3A1), a member of the ALDH superfamily is highly expressed in various cancers such as hepatoma, lung adenocarcinoma, myeloma, breast cancer etc. It has been shown to play an important role in the survival, metastasis, and chemo-resistance of cancer cells. Thus, the selective inhibition of ALDH3A1 in cancer cells could restore chemosensitivity thereby allowing lower effective dosages and reducing unwanted side effects.

BioVision's ALDH3A1 Inhibitor Screening Kit provides a quick and sensitive way for screening, studying and characterizing the potential inhibitors of ALDH3A1. In this assay, ALDH3A1 oxidizes a specific substrate and generates NADH as one of the intermediate. NADH then couples with the PicoProbeTM to form a stable fluorophore, which is measured at Ex/Em = 535/587 nm. ALDH3A1 Inhibitor Control is included in the kit to compare the efficacy of test inhibitors. The assay is high-throughput adaptable and can be performed within 30-60 min.

Figure: Inhibition of ALDH3A1 activity using ALDH3A1 inhibitor. IC50 was calculated to be 17.34 ± 0.54 μM. Assay was performed following the kit protocol.

For more information on this assay kit K2060 visit: https://www.biovision.com/aldehyde-dehydrogenase-3a1-inhi...